BR0211269A - Formulações farmacêuticas injetáveis - Google Patents

Formulações farmacêuticas injetáveis

Info

Publication number
BR0211269A
BR0211269A BR0211269-8A BR0211269A BR0211269A BR 0211269 A BR0211269 A BR 0211269A BR 0211269 A BR0211269 A BR 0211269A BR 0211269 A BR0211269 A BR 0211269A
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulations
injectable pharmaceutical
suspension
preparation
solution
Prior art date
Application number
BR0211269-8A
Other languages
English (en)
Inventor
Yasuhiro Miyako
Hideaki Tai
Kakuichi Fujikane
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of BR0211269A publication Critical patent/BR0211269A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"FORMULAçõES FARMACêUTICAS INJETáVEIS". A presente invenção refere-se a um processo para suprimir a espumação que pode ocorrer junto a preparação de uma solução ou uma suspensão. Particularmente, a presente invenção refere-se a farmacêuticos, alimentícios, e outros onde a espumação junto a preparação de uma solução ou suspensão que pode causar qualquer desvantagem, é suprimida.
BR0211269-8A 2001-07-17 2002-07-16 Formulações farmacêuticas injetáveis BR0211269A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001216617 2001-07-17
PCT/JP2002/007190 WO2003007967A1 (fr) 2001-07-17 2002-07-16 Preparation medicale pour injection parenterale

Publications (1)

Publication Number Publication Date
BR0211269A true BR0211269A (pt) 2004-08-03

Family

ID=19051074

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211269-8A BR0211269A (pt) 2001-07-17 2002-07-16 Formulações farmacêuticas injetáveis

Country Status (10)

Country Link
US (1) US7645793B2 (pt)
EP (1) EP1407775A4 (pt)
JP (1) JP4636795B2 (pt)
KR (1) KR100896375B1 (pt)
CN (1) CN1286462C (pt)
BR (1) BR0211269A (pt)
CA (1) CA2453996C (pt)
MX (1) MXPA04000450A (pt)
TW (1) TWI232102B (pt)
WO (1) WO2003007967A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108163A1 (ja) * 2003-06-04 2004-12-16 Shionogi & Co., Ltd. 低帯電性粉末の製造方法
TWI335335B (en) 2004-03-24 2011-01-01 Shionogi & Co A novel crystal of a triterpene derivative

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2836541A (en) * 1953-12-04 1958-05-27 Sterling Drug Inc Mannitol stabilized morphinepapaverine composition
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
JPS61165322A (ja) 1985-01-14 1986-07-26 Microbial Chem Res Found スパガリン類の注射用凍結乾燥製剤
US4889862A (en) 1986-08-28 1989-12-26 E. I. Du Pont De Nemours And Company Freeze-dried pharmaceutical compositions of phenylquinoline carboxylic acids
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
JPS63261426A (ja) 1987-04-17 1988-10-28 Fujitsu Ltd 用語階層構成表示方式
US5089503A (en) 1987-06-03 1992-02-18 Hoffmann-La Roche Inc. Temperature stable 5-fluorouracil compositions
JPH03193735A (ja) * 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
JP3193735B2 (ja) 1991-07-24 2001-07-30 株式会社リコー カラー画像形成装置の搬送装置
DK0628569T3 (da) 1993-06-11 1996-09-30 Shionogi & Co Triterpenderivater og endothelinreceptorantagonister indeholdende samme
JP3453188B2 (ja) 1994-05-23 2003-10-06 塩野義製薬株式会社 オレアノール酸誘導体の製造方法
ATE245447T1 (de) * 1995-06-02 2003-08-15 Shionogi & Co Inhibitor von gehirnödemen
JP3177826B2 (ja) 1995-08-29 2001-06-18 武田薬品工業株式会社 注射用粉末製剤
IT1282943B1 (it) 1995-12-27 1998-04-02 Sanofi Winthrop S P A Composizione farmaceutica iniettabile__a base di acido ursodesossicoli co o tauroursodesossicolico
JPH11209277A (ja) 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
ES2253877T3 (es) 1998-03-03 2006-06-01 SHIONOGI & CO., LTD. Composiciones farmaceuticas que contienen el inhibidor de fosfolipasa((3-(2-amino-1,2-dioxoetil)-2-etil-1-(fenilmetil)-1h-indol-4-il)oxi)acetato de sodio.
ATE416790T1 (de) 1998-06-26 2008-12-15 Otsuka Pharma Co Ltd Wasserlösliche trockene zusammensetzungen
ES2233070T3 (es) 1998-08-20 2005-06-01 ELI LILLY & COMPANY Sintesis de analogos peptidicos ciclicos modificados en el anillo.
JP2000169372A (ja) 1998-09-29 2000-06-20 Takeda Chem Ind Ltd 抗真菌薬組成物
WO2000061109A1 (fr) 1999-04-12 2000-10-19 Shionogi & Co., Ltd. Procede de production de composition medicamenteuse renfermant un compose medicamenteux hydrophobe basique
DE60015672T2 (de) 1999-08-27 2005-12-01 Rohm And Haas Co. Verfahren zum Abstrippen von Polymerdispersionen oder Polymerlösungen
US6355611B1 (en) 1999-10-27 2002-03-12 Merck & Co., Inc. Salt form of a conjugate useful in the treatment of prostate cancer
US7973064B2 (en) * 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic

Also Published As

Publication number Publication date
EP1407775A1 (en) 2004-04-14
KR100896375B1 (ko) 2009-05-08
JP4636795B2 (ja) 2011-02-23
JPWO2003007967A1 (ja) 2004-11-04
CN1286462C (zh) 2006-11-29
KR20040018470A (ko) 2004-03-03
CA2453996C (en) 2011-01-11
EP1407775A4 (en) 2007-01-10
US7645793B2 (en) 2010-01-12
US20040162344A1 (en) 2004-08-19
TWI232102B (en) 2005-05-11
MXPA04000450A (es) 2004-03-18
CA2453996A1 (en) 2003-01-30
WO2003007967A1 (fr) 2003-01-30
CN1555265A (zh) 2004-12-15

Similar Documents

Publication Publication Date Title
BR9913288A (pt) Composição antioxidante compreendendo acetil l-carnitina e ácido alfa-lipóico
BR0313060A (pt) Composições farmacêuticas aquosas de 2,6-diisopropilfenol
BRPI0407950A (pt) processo para a preparação de uma composição de higiene pessoal
BR9906915A (pt) Composição que compreende mel, ou pelo menos um óleo essencial e/ou pelo menos um derivado de um óleo essencial.
BR9915727A (pt) ésteres derivados de compostos de fenil-ciclohexila substituìdos
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
PT1086706E (pt) Composicao estabilizada que compreende um medicamento nootropico
BRPI0206636B8 (pt) composição e atividade antiviral de derivados de piperazina azaindoloxoacéticos substituídos, composições farmacêuticas que os contêm e usos
BRPI0410235A (pt) inibição de pde4, composto, composição farmacêutica, método para efetuar a inibição da enzima pde4, incrementar a cognição e/ou tratar a psicose em um paciente, método para o tratamento de um paciente que tem uma doença que envolve nìveis de camp diminuìdos, método para o tratamento de um paciente que sofre de uma doença alérgica ou inflamatória e método para o tratamento de um paciente que sofre de neurodegeneração resultante de uma doença ou de um ferimento
BR0009564A (pt) Utilização de inibidores da cyp2d6 em terapias de combinação
BR9911440A (pt) Composição para a prevenção e/ou tratamento de osteoporose e alterações devido à sìndrome de menopausa
BR0210267A (pt) Composição farmacêutica sólida, processo para preparar a mesma, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases
BR9903804A (pt) Tratamento de produtos cárneos
CL2004000803A1 (es) Producto y formula alimenticia para lactantes que comprende acido sialico (n-acido acetilneuraminico libre, sialillactosa de oligosacarido, gangliosidos y macropeptido de caseina).
BR0210028A (pt) Agentes antibacterianos
BR9914932A (pt) Processo para a manufatura de uma composição de isotretinoìna, composição de isotretinoìna micronizada, forma de dosagem unitária para administração enteral e composição farmacêutica na forma de dosagem unitária
ECSP034883A (es) Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como preparados farmaceuticos que las contienen
PA8559401A1 (es) Sales de acido succinico de 5,7,14-triazatetraciclo (10.3.1.0 2,11.0 4, 9)-hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas.
CU23043A1 (es) Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
BR0112337A (pt) Derivados de fosfolipìdeos de ácido valpróico e suas misturas
BR0215395A (pt) Compostos; processo para a preparação de um composto; composição farmacêutica; e método para o tratamento e/ou profilaxia de doenças que estão relacionadas com o nìvel de glicose no sangue
BR0209517A (pt) Composições de pró-perfume
ITMI20031311A1 (it) Formulazioni per il trattamento di disturbi artrosici.
AR038927A1 (es) Sales de acido organico
BRPI0414321B8 (pt) esterilização à alta pressão para esterilização final de preparações farmacêuticas e produtos médicos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2162 DE 12/06/2012.